Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). (Q46869287)

26 December 2017

title

Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). (English)

1 reference

26 December 2017

main subject

clinical surveillance

1 reference

inferred from title

mucopolysaccharidosis VI

1 reference

inferred from title

author

Vassili Valayannopoulos

9

object named as

Vassili Valayannopoulos

1 reference

26 December 2017

2

Roberto Giugliani

1 reference

26 December 2017

author name string

Christian J Hendriksz

1

1 reference

26 December 2017

Paul Harmatz

3

1 reference

26 December 2017

Christina Lampe

4

1 reference

26 December 2017

Ana Maria Martins

5

1 reference

26 December 2017

Gregory M Pastores

6

1 reference

26 December 2017

Robert D Steiner

7

1 reference

26 December 2017

Elisa Leão Teles

8

1 reference

26 December 2017

CSP Study Group

10

1 reference

26 December 2017

publication date

30 November 2011

1 reference

26 December 2017

Journal of Inherited Metabolic Disease

published in

1 reference

26 December 2017

volume

36

1 reference

26 December 2017

page(s)

373-384

1 reference

26 December 2017

issue

2

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/s10545-011-9410-9

exact match

0 references

cites work

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Management guidelines for mucopolysaccharidosis VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Mutational analysis of 105 mucopolysaccharidosis type VI patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme])

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Echocardiographic study of paediatric patients with mucopolysaccharidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

The status of hematopoietic stem cell transplantation in lysosomal storage disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Mucopolysaccharidosis VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Initial report from the Hunter Outcome Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9410-9

Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders--clinical and echocardiographic findings in 64 patients

21 January 2018

1 reference

12 December 2020

The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study

1 reference

12 December 2020

Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I

1 reference

12 December 2020

Brain MRI in mucopolysaccharidosis: Effect of aging and correlation with biochemical findings

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

1 reference

12 December 2020

Cumulative incidence rates of the mucopolysaccharidoses in Germany

1 reference

12 December 2020

The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I

1 reference

12 December 2020

Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.

1 reference

12 December 2020

10.1007/S10545-011-9410-9

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

22127392

1 reference

26 December 2017